Stay updated on Pediatric CNS Malignancies Study: Nivolumab Combo Clinical Trial
Sign up to get notified when there's something new on the Pediatric CNS Malignancies Study: Nivolumab Combo Clinical Trial page.

Latest updates to the Pediatric CNS Malignancies Study: Nivolumab Combo Clinical Trial page
- Check5 days agoChange DetectedThe website footer now displays revision v3.8.1 instead of v3.8.0.SummaryDifference0.0%

- Check12 days agoChange DetectedThe record now presents details for the completed pediatric CNS malignancy trial of nivolumab alone or with ipilimumab, including its eligibility criteria, study design, outcomes, and participating locations. It also includes publication, record-history, and study-document information.SummaryDifference83%

- Check19 days agoChange DetectedThe displayed site revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedA general NIH website-transition notice appears above the ClinicalTrials.gov page, which continues to show a 403 error instead of the study record. The footer revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study record content with an access-denied message. This reflects that the study information is no longer accessible on the page, rather than updates to the study details themselves.SummaryDifference19%

Stay in the know with updates to Pediatric CNS Malignancies Study: Nivolumab Combo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pediatric CNS Malignancies Study: Nivolumab Combo Clinical Trial page.